Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population

Ritu Kumari, Ram Lakhan, R K Garg, J Kalita, U K Misra, Balraj Mittal, Ritu Kumari, Ram Lakhan, R K Garg, J Kalita, U K Misra, Balraj Mittal

Abstract

Background: In epilepsy, in spite of the best possible medications and treatment protocols, approximately one-third of the patients do not respond adequately to anti-epileptic drugs. Such interindividual variations in drug response are believed to result from genetic variations in candidate genes belonging to multiple pathways.

Materials and methods: In the present pharmacogenetic analysis, a total of 402 epilepsy patients were enrolled. Of them, 128 were diagnosed as multiple drug-resistant epilepsy and 274 patients were diagnosed as having drug-responsive epilepsy. We selected a total of 10 candidate gene polymorphisms belonging to three major classes, namely drug transporters, drug metabolizers and drug targets. These genetic polymorphism included CYP2C9 c.430C>T (*2 variant), CYP2C9 c.1075 A>C (*3 variant), ABCB1 c.3435C>T, ABCB1c.1236C>T, ABCB1c.2677G>T/A, SCN1A c.3184 A> G, SCN2A c.56G>A (p.R19K), GABRA1c.IVS11 + 15 A>G and GABRG2 c.588C>T. Genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methods, and each genotype was confirmed via direct DNA sequencing. The relationship between various genetic polymorphisms and responsiveness was examined using binary logistic regression by SPSS statistical analysis software.

Results: CYP2C9 c.1075 A>C polymorphism showed a marginal significant difference between drug resistance and drug-responsive patients for the AC genotype (Odds ratio [OR] = 0.57, 95% confidence interval [CI] = 0.32-1.00; P = 0.05). In drug transporter, ABCB1c.2677G>T/A polymorphism, allele A was associated with drug-resistant phenotype in epilepsy patients (P = 0.03, OR = 0.31, 95% CI = 0.10-0.93). Similarly, the variant allele frequency of SCN2A c.56 G>A single nucleotide polymorphism was significantly higher in drug-resistant patients (P = 0.03; OR = 1.62, 95% CI = 1.03, 2.56). We also observed a significant difference at the genotype as well as allele frequencies of GABRA1c.IVS11 + 15 A > G polymorphism in drug-resistant patients for homozygous GG genotype (P = 0.03, OR = 1.84, 95% CI = 1.05-3.23) and G allele (P = 0.02, OR = 1.43, 95% CI = 1.05-1.95).

Conclusions: Our results showed that pharmacogenetic variants have important roles in epilepsy at different levels. It may be noted that multi-factorial diseases like epilepsy are also regulated by various other factors that may also be considered in the future.

Keywords: Drug resistance; epilepsy; pharmacogenomics.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Szoeke CE, Newton M, Wood JM, Goldstein D, Berkovic SF, OBrien TJ, et al. Update on pharmacogenetics in epilepsy: A brief review. Lancet Neurol. 2006;5:189–96.
    1. Mann MW, Pons G. Drug resistance in partial epilepsy: Epidemiology, mechanisms, pharmacogenetics and therapeutical aspects. Neurochirurgie. 2008;54:259–64.
    1. Wilson JF, Weale ME, Smith AC, Gratrix F, Fletcher B, et al. Population genetic structure of variable drug response. Nat Genet. 2001;29:265–9.
    1. Jimenez-Sanchez G. Developing a platform for genomic medicine in Mexico. Science. 2003;300:295–6.
    1. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. Detection of large-scale variation in the human genome. Nat Genet. 2004;36:949–51.
    1. McCorry D, Chadwick D, Marson A. Current drug treatment of epilepsy in adults. Lancet Neurol. 2004;3:729–35.
    1. Browne TR. Pharmacokinetics of antiepileptic drugs. Neurology. 1998;51:S2–7.
    1. Ferraro TN, Buono RJ. The relationship between the pharmacology of antiepileptic drugs and human gene variation: An overview. Epilepsy Behav. 2005;7:18–36.
    1. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrugresistance gene (P-glycoprotein) isexpressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86:695–8.
    1. Ghersi-Egea JF, Strazielle N. Choroid plexus transporters for drugs and other xenobiotics. J Drug Target. 2002;10:353–7.
    1. Kwan P, Baum L, Wong V, Ng PW, Lui CH, Sin NC, et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 2007;11:112–7.
    1. Löscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. 2006;47:1253–84.
    1. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia. 2005;46:643–7.
    1. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adín J. Ion channelsand epilepsy. Curr Pharm Des. 2005;11:1975–2003.
    1. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in north Indian population. Br J Clin Pharmacol. 2009;68:214–20.
    1. Moshe SL. Mechanisms of action of anticonvulsant agents. Neurology. 2000;55:S32–40.
    1. Bethmann K, Fritschy JM, Brandt C, Loscher W. Antiepileptic drug resistant rats differ from drug responsive rats in GABA A receptor subunit expression in a model of temporal lobe epilepsy. Neurobiol Dis. 2008;31:169–87.
    1. Ramachandran V, Shorvon SD. Clues to the genetic influences of drug responsiveness in epilepsy. Epilepsia. 2003;44:33–7.
    1. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003;348:1442–8.
    1. Lakhan R, Misra UK, Kalita J, Pradhan S, Gogtay NJ, Singh MK, et al. No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. Epilepsy Behav. 2008;4:78–82.
    1. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
    1. Aynacioglu AS, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol. 1999;8:409–15.
    1. Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol. 2003;55:560–9.
    1. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169–74.
    1. Chou IC, Peng CT, Tsai FJ, Huang CC, Shi YR, Tsai CH. The lack of association between febrile convulsions and polymorphisms in SCN1A. Epilepsy Res. 2003;54:53–7.
    1. Haug K, Hallmann K, Rebstock J, Dullinger J, Muth S, Haverkamp F, et al. The voltage-gated sodium channel gene SCN2A and idiopathic generalized epilepsy. Epilepsy Res. 2001;47:243–6.
    1. Park CS, Park SY, Lee CS, Sohn JW, Hahn GH, Kim BJ. Association between alcoholism and the genetic polymorphisms of the GABAA receptor genes on chromosome 5q33–34 in Korean population. J Korean Med Sci. 2006;21:533–8.
    1. Chou IC, Lee CC, Tsai CH, Tsai Y, Wan L, Hsu YA, et al. Association of GABRG2 polymorphisms with idiopathic generalized epilepsy. Pediatr Neurol. 2007;36:40–4.
    1. Chantal D. The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol. 2006;10:57–65.
    1. van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics. 2001;11:287–91.
    1. Anderson GD. Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit. 2008;30:173–80.
    1. Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit. 2004;26:534–40.
    1. Simon C, Stieger B, Kullak-Ublick GA, Fried M, Mueller S, Fritschy JM, et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand. 2007;115:232–42.
    1. Berg AT, Kelly MM. Defining Intractability: Comparisons among Published Definitions. Epilepsia. 2006;47:431–6.
    1. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential Role of Sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in north Indian population. Br J Clin Pharmacol. 2009;68:214–20.
    1. Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: Correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics. 2008;18:989–98.
    1. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005;102:5507–12.
    1. Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL, Sisodiya SM, Goldstein DB, Liou HH. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics. 2006;16:721–6.
    1. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol. 2008;66:304–7.
    1. Benarroch EE. GABAA receptor heterogeneity, function, and implications for epilepsy. Neurology. 2007;68:612–4.
    1. Krampfl K, Maljevic S, Cossette P, Ziegler E, Rouleau GA, Lerche H, et al. Molecular analysis of the A322D mutation in the GABA receptor alpha-subunit causing juvenile myoclonic epilepsy. Eur J Neurosci. 2005;22:10–20.
    1. Lakhan R, Kalita J, Misra UK, Mittal B. Association of alpha subunit of GABAA receptor subtype gene polymorphisms with epilepsy susceptibility and drug resistance in north Indian population. Seizure. 2010;19:237–41.
    1. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: Effect of past treatment history. Neurology. 2008;70:54–65.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する